**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Bhavani Mandava, IMS & SUM Hospital, SOA University, Bhubaneswar, Odisha.
email : bhavs.potluri1@gmail.com
Contact number : +91 9848039004

**Main Body of the Abstract**
AL Amyloidosis is an uncommon plasma cell disorder that presents with non-specific symptoms which often lead to either misdiagnosis or delayed diagnosis. The outcome of AL Amyloidosis depends on age, early detection, treatment and the extent of organ or system involvement.
Aim of the study
To study the diagnostic challenges in AL Amyloidosis, their effect on organ involvement and prognosis of patients in a single centre
Materials and Methods
A total of 16  patients diagnosed with AL Amyloidosis between June 2019 and June 2023 were evaluated for the delay in diagnosis, organ involvement, prognosis and outcomes.
Results 
Out of 16 patients, 12 were males and 4 were females. The median age of presentation was 53 years  (42-71years). Most patients initially presented to nephrologist followed by general practitioner then cardiologist. The median time taken for diagnosis was 9.3 months from the first symptom onset. The most common presenting symptoms were pedal edema, shortness of breath and generalized weakness in 62.5%(10 patients).  More than two organ involvement is seen in 50%(8) of patients and the most common organs involved were kidney and heart. Most of our patients received CyborD regimen(14), 2 patients received Dara-CyborD followed by an Autologous stem cell transplant. Mortality was observed in 37.5%(6) with the most common cause of death being cardiac related.
Conclusion
In AL amyloidosis vague presentation with non-specific symptoms is associated with misdiagnosis or delayed diagnosis. Delayed diagnosis and involvement of more than 2 organs especially severe cardiac involvement were associated with poor prognosis.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Bhavani Mandava, IMS & SUM Hospital, SOA University, Bhubaneswar, Odisha.
email : bhavs.potluri1@gmail.com
Contact number : +91 9848039004

**Main Body of the Abstract**
AL Amyloidosis is an uncommon plasma cell disorder that presents with non-specific symptoms which often lead to either misdiagnosis or delayed diagnosis. The outcome of AL Amyloidosis depends on age, early detection, treatment and the extent of organ or system involvement.
**Aim of the study**
To study the diagnostic challenges in AL Amyloidosis, their effect on organ involvement and prognosis of patients in a single centre
**Materials and Methods**
A total of 16  patients diagnosed with AL Amyloidosis between June 2019 and June 2023 were evaluated for the delay in diagnosis, organ involvement, prognosis and outcomes.
**Results** 
Out of 16 patients, 12 were males and 4 were females. The median age of presentation was 53 years  (42-71years). Most patients initially presented to nephrologist followed by general practitioner then cardiologist. The median time taken for diagnosis was 9.3 months from the first symptom onset. The most common presenting symptoms were pedal edema, shortness of breath and generalized weakness in 62.5%(10 patients).  More than two organ involvement is seen in 50%(8) of patients and the most common organs involved were kidney and heart. Most of our patients received CyborD regimen(14), 2 patients received Dara-CyborD followed by an Autologous stem cell transplant. Mortality was observed in 37.5%(6) with the most common cause of death being cardiac related.
**Conclusion**
In AL amyloidosis vague presentation with non-specific symptoms is associated with misdiagnosis or delayed diagnosis. Delayed diagnosis and involvement of more than 2 organs especially severe cardiac involvement were associated with poor prognosis.



Is Al Amyloidosis A Diagnostic Puzzle Or Rare Entity: A single centre experience PA81 (#484)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.